| Us 2 Behavioral Health Care Inc | |
|
119 N Mccarthy Rd Ste P Appleton WI 54913-9112 | |
| (920) 903-1060 | |
| (920) 903-1164 |
| Full Name | Us 2 Behavioral Health Care Inc |
|---|---|
| Speciality | Counselor |
| Location | 119 N Mccarthy Rd Ste P, Appleton, Wisconsin |
| Authorized Official Name and Position | Sheng B Lee Yang (EXECUTIVE DIRECTOR) |
| Authorized Official Contact | 9208501490 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Us 2 Behavioral Health Care Inc 119 N Mccarthy Rd Ste P Appleton WI 54913-9112 Ph: (920) 903-1060 | Us 2 Behavioral Health Care Inc 119 N Mccarthy Rd Ste P Appleton WI 54913-9112 Ph: (920) 903-1060 |
| NPI Number | 1083268635 |
|---|---|
| Provider Enumeration Date | 07/31/2019 |
| Last Update Date | 08/16/2022 |
| Certification Date | 08/16/2022 |
| Medicare PECOS PAC ID | 1557691151 |
|---|---|
| Medicare Enrollment ID | O20191024000284 |
News Archive
Jefferson's Kimmel Cancer Center and the Department of Radiology at Thomas Jefferson University received a five-year, $2.6 million grant from the National Institutes of Health (NIH) to investigate a potentially revolutionary method that can stage prostate cancers and detect recurrent disease so accurately, it would significantly reduce the number of confirmation biopsies. Such biopsies can be invasive, costly, and often lead to false-positive readings.
In 2018 the International Osteoporosis Foundation and European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis published the updated European guidance for the diagnosis and management of osteoporosis in postmenopausal women.
A new study from Columbia University Medical Center researchers at NewYork-Presbyterian Hospital/Columbia, who are members of the Southwest Oncology Group (SWOG), suggests that certain changes in prostate-specific antigen (PSA) levels may serve as surrogate endpoints for prostate cancer survival.
XTL Biopharmaceuticals Ltd., a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of unmet clinical needs, announced today that Israeli biotech investor Alex Rabinovich, its largest shareholder, increased his stake in the Company through his investment in InterCure, an XTL subsidiary, and recent purchases of XTL stock in the market.
Facial injections of polylactic acid, a synthetic biodegradable polymer, may help improve the debilitating facial lipoatrophy (loss of fat in the face) associated with HIV infection and its treatment, according to an article in the March issue of Archives of Dermatology.
› Verified 6 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1083268635 | NPI | - | NPPES |
| 1000042518 | Medicaid | WI | |
| 1649671629 | Other | WI | NPI |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 101YP2500X | Counselor - Professional | (* (Not Available)) | Primary |
| Provider Name | Sheng Boualong Lee Yang |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1649671629 PECOS PAC ID: 2466782065 Enrollment ID: I20191024000460 |
News Archive
Jefferson's Kimmel Cancer Center and the Department of Radiology at Thomas Jefferson University received a five-year, $2.6 million grant from the National Institutes of Health (NIH) to investigate a potentially revolutionary method that can stage prostate cancers and detect recurrent disease so accurately, it would significantly reduce the number of confirmation biopsies. Such biopsies can be invasive, costly, and often lead to false-positive readings.
In 2018 the International Osteoporosis Foundation and European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis published the updated European guidance for the diagnosis and management of osteoporosis in postmenopausal women.
A new study from Columbia University Medical Center researchers at NewYork-Presbyterian Hospital/Columbia, who are members of the Southwest Oncology Group (SWOG), suggests that certain changes in prostate-specific antigen (PSA) levels may serve as surrogate endpoints for prostate cancer survival.
XTL Biopharmaceuticals Ltd., a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of unmet clinical needs, announced today that Israeli biotech investor Alex Rabinovich, its largest shareholder, increased his stake in the Company through his investment in InterCure, an XTL subsidiary, and recent purchases of XTL stock in the market.
Facial injections of polylactic acid, a synthetic biodegradable polymer, may help improve the debilitating facial lipoatrophy (loss of fat in the face) associated with HIV infection and its treatment, according to an article in the March issue of Archives of Dermatology.
› Verified 6 days ago
| Provider Name | Kinsey Beth Pierre |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1346735891 PECOS PAC ID: 7911338207 Enrollment ID: I20200521001252 |
News Archive
Jefferson's Kimmel Cancer Center and the Department of Radiology at Thomas Jefferson University received a five-year, $2.6 million grant from the National Institutes of Health (NIH) to investigate a potentially revolutionary method that can stage prostate cancers and detect recurrent disease so accurately, it would significantly reduce the number of confirmation biopsies. Such biopsies can be invasive, costly, and often lead to false-positive readings.
In 2018 the International Osteoporosis Foundation and European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis published the updated European guidance for the diagnosis and management of osteoporosis in postmenopausal women.
A new study from Columbia University Medical Center researchers at NewYork-Presbyterian Hospital/Columbia, who are members of the Southwest Oncology Group (SWOG), suggests that certain changes in prostate-specific antigen (PSA) levels may serve as surrogate endpoints for prostate cancer survival.
XTL Biopharmaceuticals Ltd., a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of unmet clinical needs, announced today that Israeli biotech investor Alex Rabinovich, its largest shareholder, increased his stake in the Company through his investment in InterCure, an XTL subsidiary, and recent purchases of XTL stock in the market.
Facial injections of polylactic acid, a synthetic biodegradable polymer, may help improve the debilitating facial lipoatrophy (loss of fat in the face) associated with HIV infection and its treatment, according to an article in the March issue of Archives of Dermatology.
› Verified 6 days ago
| Provider Name | Trisha Ann Picard |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1235614371 PECOS PAC ID: 0648676759 Enrollment ID: I20210914003327 |
News Archive
Jefferson's Kimmel Cancer Center and the Department of Radiology at Thomas Jefferson University received a five-year, $2.6 million grant from the National Institutes of Health (NIH) to investigate a potentially revolutionary method that can stage prostate cancers and detect recurrent disease so accurately, it would significantly reduce the number of confirmation biopsies. Such biopsies can be invasive, costly, and often lead to false-positive readings.
In 2018 the International Osteoporosis Foundation and European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis published the updated European guidance for the diagnosis and management of osteoporosis in postmenopausal women.
A new study from Columbia University Medical Center researchers at NewYork-Presbyterian Hospital/Columbia, who are members of the Southwest Oncology Group (SWOG), suggests that certain changes in prostate-specific antigen (PSA) levels may serve as surrogate endpoints for prostate cancer survival.
XTL Biopharmaceuticals Ltd., a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of unmet clinical needs, announced today that Israeli biotech investor Alex Rabinovich, its largest shareholder, increased his stake in the Company through his investment in InterCure, an XTL subsidiary, and recent purchases of XTL stock in the market.
Facial injections of polylactic acid, a synthetic biodegradable polymer, may help improve the debilitating facial lipoatrophy (loss of fat in the face) associated with HIV infection and its treatment, according to an article in the March issue of Archives of Dermatology.
› Verified 6 days ago
| Provider Name | Chloe Day Anderson Kemp |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1164077103 PECOS PAC ID: 6608273784 Enrollment ID: I20210916002963 |
News Archive
Jefferson's Kimmel Cancer Center and the Department of Radiology at Thomas Jefferson University received a five-year, $2.6 million grant from the National Institutes of Health (NIH) to investigate a potentially revolutionary method that can stage prostate cancers and detect recurrent disease so accurately, it would significantly reduce the number of confirmation biopsies. Such biopsies can be invasive, costly, and often lead to false-positive readings.
In 2018 the International Osteoporosis Foundation and European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis published the updated European guidance for the diagnosis and management of osteoporosis in postmenopausal women.
A new study from Columbia University Medical Center researchers at NewYork-Presbyterian Hospital/Columbia, who are members of the Southwest Oncology Group (SWOG), suggests that certain changes in prostate-specific antigen (PSA) levels may serve as surrogate endpoints for prostate cancer survival.
XTL Biopharmaceuticals Ltd., a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of unmet clinical needs, announced today that Israeli biotech investor Alex Rabinovich, its largest shareholder, increased his stake in the Company through his investment in InterCure, an XTL subsidiary, and recent purchases of XTL stock in the market.
Facial injections of polylactic acid, a synthetic biodegradable polymer, may help improve the debilitating facial lipoatrophy (loss of fat in the face) associated with HIV infection and its treatment, according to an article in the March issue of Archives of Dermatology.
› Verified 6 days ago
| Provider Name | Mckenna Garvey |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1508484833 PECOS PAC ID: 7911398144 Enrollment ID: I20211227000155 |
News Archive
Jefferson's Kimmel Cancer Center and the Department of Radiology at Thomas Jefferson University received a five-year, $2.6 million grant from the National Institutes of Health (NIH) to investigate a potentially revolutionary method that can stage prostate cancers and detect recurrent disease so accurately, it would significantly reduce the number of confirmation biopsies. Such biopsies can be invasive, costly, and often lead to false-positive readings.
In 2018 the International Osteoporosis Foundation and European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis published the updated European guidance for the diagnosis and management of osteoporosis in postmenopausal women.
A new study from Columbia University Medical Center researchers at NewYork-Presbyterian Hospital/Columbia, who are members of the Southwest Oncology Group (SWOG), suggests that certain changes in prostate-specific antigen (PSA) levels may serve as surrogate endpoints for prostate cancer survival.
XTL Biopharmaceuticals Ltd., a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of unmet clinical needs, announced today that Israeli biotech investor Alex Rabinovich, its largest shareholder, increased his stake in the Company through his investment in InterCure, an XTL subsidiary, and recent purchases of XTL stock in the market.
Facial injections of polylactic acid, a synthetic biodegradable polymer, may help improve the debilitating facial lipoatrophy (loss of fat in the face) associated with HIV infection and its treatment, according to an article in the March issue of Archives of Dermatology.
› Verified 6 days ago
| Provider Name | Isaac Theodore Kabacinski |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1366060469 PECOS PAC ID: 3072981893 Enrollment ID: I20230411002399 |
News Archive
Jefferson's Kimmel Cancer Center and the Department of Radiology at Thomas Jefferson University received a five-year, $2.6 million grant from the National Institutes of Health (NIH) to investigate a potentially revolutionary method that can stage prostate cancers and detect recurrent disease so accurately, it would significantly reduce the number of confirmation biopsies. Such biopsies can be invasive, costly, and often lead to false-positive readings.
In 2018 the International Osteoporosis Foundation and European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis published the updated European guidance for the diagnosis and management of osteoporosis in postmenopausal women.
A new study from Columbia University Medical Center researchers at NewYork-Presbyterian Hospital/Columbia, who are members of the Southwest Oncology Group (SWOG), suggests that certain changes in prostate-specific antigen (PSA) levels may serve as surrogate endpoints for prostate cancer survival.
XTL Biopharmaceuticals Ltd., a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of unmet clinical needs, announced today that Israeli biotech investor Alex Rabinovich, its largest shareholder, increased his stake in the Company through his investment in InterCure, an XTL subsidiary, and recent purchases of XTL stock in the market.
Facial injections of polylactic acid, a synthetic biodegradable polymer, may help improve the debilitating facial lipoatrophy (loss of fat in the face) associated with HIV infection and its treatment, according to an article in the March issue of Archives of Dermatology.
› Verified 6 days ago
| Provider Name | Morgan J Gald |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1215688098 PECOS PAC ID: 7618321670 Enrollment ID: I20230925001124 |
News Archive
Jefferson's Kimmel Cancer Center and the Department of Radiology at Thomas Jefferson University received a five-year, $2.6 million grant from the National Institutes of Health (NIH) to investigate a potentially revolutionary method that can stage prostate cancers and detect recurrent disease so accurately, it would significantly reduce the number of confirmation biopsies. Such biopsies can be invasive, costly, and often lead to false-positive readings.
In 2018 the International Osteoporosis Foundation and European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis published the updated European guidance for the diagnosis and management of osteoporosis in postmenopausal women.
A new study from Columbia University Medical Center researchers at NewYork-Presbyterian Hospital/Columbia, who are members of the Southwest Oncology Group (SWOG), suggests that certain changes in prostate-specific antigen (PSA) levels may serve as surrogate endpoints for prostate cancer survival.
XTL Biopharmaceuticals Ltd., a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of unmet clinical needs, announced today that Israeli biotech investor Alex Rabinovich, its largest shareholder, increased his stake in the Company through his investment in InterCure, an XTL subsidiary, and recent purchases of XTL stock in the market.
Facial injections of polylactic acid, a synthetic biodegradable polymer, may help improve the debilitating facial lipoatrophy (loss of fat in the face) associated with HIV infection and its treatment, according to an article in the March issue of Archives of Dermatology.
› Verified 6 days ago
News Archive
Jefferson's Kimmel Cancer Center and the Department of Radiology at Thomas Jefferson University received a five-year, $2.6 million grant from the National Institutes of Health (NIH) to investigate a potentially revolutionary method that can stage prostate cancers and detect recurrent disease so accurately, it would significantly reduce the number of confirmation biopsies. Such biopsies can be invasive, costly, and often lead to false-positive readings.
In 2018 the International Osteoporosis Foundation and European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis published the updated European guidance for the diagnosis and management of osteoporosis in postmenopausal women.
A new study from Columbia University Medical Center researchers at NewYork-Presbyterian Hospital/Columbia, who are members of the Southwest Oncology Group (SWOG), suggests that certain changes in prostate-specific antigen (PSA) levels may serve as surrogate endpoints for prostate cancer survival.
XTL Biopharmaceuticals Ltd., a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of unmet clinical needs, announced today that Israeli biotech investor Alex Rabinovich, its largest shareholder, increased his stake in the Company through his investment in InterCure, an XTL subsidiary, and recent purchases of XTL stock in the market.
Facial injections of polylactic acid, a synthetic biodegradable polymer, may help improve the debilitating facial lipoatrophy (loss of fat in the face) associated with HIV infection and its treatment, according to an article in the March issue of Archives of Dermatology.
› Verified 6 days ago
A Beautiful Journey, Llc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 1011 N Lynndale Dr Ste 2d, Appleton, WI 54914 Phone: 920-268-3242 | |
Walk By Faith Counseling, Llc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 412 E Longview Dr Ste C, Appleton, WI 54911 Phone: 920-238-3340 Fax: 920-325-0198 | |
Be. // Child And Adolescent Mental Health Llc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 1309 S Oneida St, Appleton, WI 54915 Phone: 920-903-8841 | |
Acs Clinical Services Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 720 W Washington St, Appleton, WI 54914 Phone: 920-830-1750 Fax: 920-830-1770 | |
Livelihood Counseling, Llc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 477 S Nicolet Rd Ste 1, Appleton, WI 54914 Phone: 920-944-9700 Fax: 920-570-6990 | |
Christian Family Counseling Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 5300 N Meade St, Appleton, WI 54913 Phone: 800-438-1772 Fax: 262-293-9737 | |
Badger Counseling Llc Mental Health Clinic Medicare: Medicare Enrolled Practice Location: 436 E Longview Dr Ste A, Appleton, WI 54911 Phone: 920-239-5017 |